{"id":"cyclosporione-a-withdrawal","safety":{"commonSideEffects":[{"rate":null,"effect":"Organ rejection (in transplant patients)"},{"rate":null,"effect":"Disease flare or relapse (in autoimmune conditions)"},{"rate":null,"effect":"Rebound inflammation"}]},"_chembl":{"chemblId":"CHEMBL1788132","moleculeType":"Small molecule","molecularWeight":"295.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is not a drug itself but rather a clinical protocol for safely discontinuing cyclosporine A, an established immunosuppressant used in transplantation and autoimmune conditions. The withdrawal process requires careful monitoring to prevent rejection episodes or disease flares. Cyclosporine A normally works by blocking calcineurin-dependent T-cell proliferation; withdrawal necessitates gradual dose reduction and close clinical surveillance.","oneSentence":"Cyclosporine A withdrawal refers to the clinical management of discontinuing cyclosporine A therapy, which involves tapering an immunosuppressant that inhibits calcineurin and T-cell activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:44:03.470Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Management protocol for discontinuation of cyclosporine A in transplant recipients"},{"name":"Management protocol for discontinuation of cyclosporine A in autoimmune disease patients"}]},"trialDetails":[{"nctId":"NCT00148252","phase":"PHASE4","title":"Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant","status":"TERMINATED","sponsor":"University of Oslo School of Pharmacy","startDate":"2003-02","conditions":"Renal Transplantation","enrollment":298}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cyclosporione A withdrawal","genericName":"Cyclosporione A withdrawal","companyName":"University of Oslo School of Pharmacy","companyId":"university-of-oslo-school-of-pharmacy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine A withdrawal refers to the clinical management of discontinuing cyclosporine A therapy, which involves tapering an immunosuppressant that inhibits calcineurin and T-cell activation. Used for Management protocol for discontinuation of cyclosporine A in transplant recipients, Management protocol for discontinuation of cyclosporine A in autoimmune disease patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}